Adverum Biotechnologies (ADVM) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most powerful forces ...

Adverum will sell the shares at a price per share of $1.20, representing a premium of approximately 20% to its stock’s 30-day volume-weighted average price, and the financing is expected to close on ...

Adverum Biotechnologies, Inc. ADVM announced that it has completed the investigational new drug (“IND”) amendment with the FDA to begin a mid-stage study on its gene therapy candidate, ADVM-022, for ...

At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (Recession is Imminent: We Need A Travel Ban NOW).

Adverum Biotechnologies, Inc. ADVM announced that it has received feedback from the FDA on its investigational new drug (IND) application for initiating a phase II study to evaluate its eye disorder ...

Adverum Biotechnologies stock rose 20% over the last 10 trading days (2 weeks), compared to the broader market (S&P500) rise of 3.5% A change of 20% or more over 10 trading days is a 33% likelihood ...

Hedge funds and other investment firms run by legendary investors like Israel Englander and Ray Dalio are entrusted to manage billions of dollars of accredited investors’ money because they are ...

Adverum Biotechnologies Inc (NASDAQ:ADVM) released data from its ongoing LUNA Phase 2 trial for Ixo-vec in patients with wet age-related macular degeneration (AMD). The 26-week interim analysis was ...

Adverum Biotechnologies, Inc. (NASDAQ:ADVM) is among the best fundamentally strong penny stocks to buy right now. During the first quarter, Trexquant Investment LP reduced its stake in Adverum ...